what is the drug tirzepatide New Breakthrough Obesity Drug

Whichever method you use, be sure to first remove all personal information on the prescription label or use a permanent marker to cover it

Pregnant or breastfeeding individuals should not use GLP-1 medications

The SELECT trial, published in 2023, additionally demonstrated that semaglutide reduces the risk of major cardiovascular events in adults with obesity and established cardiovascular disease suggesting cardiovascular benefit that extends beyond weight loss alone

Factors that may increase risk include pre-existing digestive conditions, dietary choices high in sulphur-containing foods, rapid eating habits, and concurrent medications affecting gut motility